TOKYO, Mar 27 (Pulse News Wire) – Medinet CO.,LTD. (2370.T) announced changes to the expenditure schedule for funds raised through the issuance of subscription warrants.
At today’s board meeting, the company decided to adjust the planned spending timeline for certain regenerative medical product development projects originally disclosed on Aug 29, 2025. Specifically, the adjustments involve: For the 15th tranche of subscription warrants, previously allocated funds totaling ¥398 million were set to be spent between October 2019 and March 2026. Now, expenditures related to chronic heart failure treatment research will cease in September 2021, while development costs for glyco-modified T-cell products will end in July 2025. Remaining funds for general product development expenses will now extend until September 2027, increasing the total unspent amount to ¥50 million.
Regarding the 16th tranche, initially scheduled for disbursement up to March 2026, the revised plan extends the timelines for regenerative medical product development and joint research with the National Cancer Center until September 2027. Additionally, funding for collaborative studies with Kyoto Prefectural University of Medicine remains unchanged but will still be managed securely until needed. As of February 28, 2026, all 15th and 16th tranches of subscription warrants have been fully exercised, raising a combined ¥(¥398 million) million. Unallocated funds amounting to ¥(¥50 million) million and ¥(¥777 million) million for the respective tranches are being held safely in banks pending further deployment.
The company noted that these adjustments would have a minor impact on its fiscal year ending September 2026.
🟢 Confidence: High AI-translated content.